Cabot (NYSE:CBT) Stock Rating Lowered by StockNews.com

Cabot (NYSE:CBT) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

Several other analysts have also recently weighed in on CBT. JPMorgan Chase & Co. decreased their price objective on shares of Cabot from $105.00 to $85.00 and set an “underweight” rating on the stock in a research note on Friday, February 21st. UBS Group decreased their price target on Cabot from $93.00 to $83.00 and set a “neutral” rating on the stock in a research report on Monday. Finally, Mizuho dropped their price target on Cabot from $122.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $93.25.

Cabot Stock Performance

NYSE:CBT opened at $74.69 on Wednesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.29 and a current ratio of 2.00. The firm’s 50-day moving average is $84.10 and its 200-day moving average is $96.66. Cabot has a 52-week low of $73.63 and a 52-week high of $117.46. The company has a market cap of $4.05 billion, a price-to-earnings ratio of 9.92, a PEG ratio of 0.74 and a beta of 1.04.

Cabot (NYSE:CBT) last announced its quarterly earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. Equities research analysts anticipate that Cabot will post 7.57 earnings per share for the current year.

Institutional Trading of Cabot

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its holdings in shares of Cabot by 10.7% in the fourth quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company’s stock worth $123,000 after acquiring an additional 130 shares in the last quarter. Personal CFO Solutions LLC increased its stake in Cabot by 3.3% during the 4th quarter. Personal CFO Solutions LLC now owns 4,285 shares of the specialty chemicals company’s stock worth $391,000 after purchasing an additional 137 shares in the last quarter. Isthmus Partners LLC increased its stake in Cabot by 4.8% during the 4th quarter. Isthmus Partners LLC now owns 4,072 shares of the specialty chemicals company’s stock worth $372,000 after purchasing an additional 187 shares in the last quarter. Neuberger Berman Group LLC lifted its stake in Cabot by 1.2% in the fourth quarter. Neuberger Berman Group LLC now owns 18,238 shares of the specialty chemicals company’s stock valued at $1,665,000 after buying an additional 212 shares in the last quarter. Finally, M&T Bank Corp boosted its holdings in shares of Cabot by 0.4% in the third quarter. M&T Bank Corp now owns 50,221 shares of the specialty chemicals company’s stock valued at $5,614,000 after buying an additional 213 shares during the period. Institutional investors and hedge funds own 93.18% of the company’s stock.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.